Revisiting the role of ABC transporters in multidrug-resistant cancer
Most patients who die of cancer have disseminated disease that has become resistant to
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP …
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP …
Current challenges and opportunities in treating glioblastoma
A Shergalis, A Bankhead III, U Luesakul… - Pharmacological …, 2018 - Elsevier
Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, has
a high mortality rate despite extensive efforts to develop new treatments. GBM exhibits both …
a high mortality rate despite extensive efforts to develop new treatments. GBM exhibits both …
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …
representing a highly heterogeneous group of neoplasms that are among the most …
Targeting cellular pathways in glioblastoma multiforme
JRD Pearson, T Regad - Signal transduction and targeted therapy, 2017 - nature.com
Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor
prognosis, short median patient survival and a very limited response to therapies. GBM has …
prognosis, short median patient survival and a very limited response to therapies. GBM has …
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary
causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding …
causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding …
ABCB1 and ABCG2 regulation at the blood-brain barrier: potential new targets to improve brain drug delivery
The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery
of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely …
of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely …
Glioma: experimental models and reality
K Lenting, R Verhaak, M Ter Laan, P Wesseling… - Acta …, 2017 - Springer
In theory, in vitro and in vivo models for human gliomas have great potential to not only
enhance our understanding of glioma biology, but also to facilitate the development of novel …
enhance our understanding of glioma biology, but also to facilitate the development of novel …
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
K Natarajan, Y Xie, MR Baer, DD Ross - Biochemical pharmacology, 2012 - Elsevier
Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance
protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter …
protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter …
EGFR as a clinical marker in glioblastomas and other gliomas
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …